Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Read More

Overview

Feature Articles

Latest Prostate Cancer News and Research

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

AI model could help clinicians to understand prostate tumor's aggressiveness

AI model could help clinicians to understand prostate tumor's aggressiveness

Urine transcriptomics: A new frontier for non-invasive genitourinary disease detection

Urine transcriptomics: A new frontier for non-invasive genitourinary disease detection

Study identifies six cancer susceptibility genes

Study identifies six cancer susceptibility genes

Study uncovers six cancer susceptibility genes

Study uncovers six cancer susceptibility genes

Space-based research uncovers key to cancer cell survival

Space-based research uncovers key to cancer cell survival

New research unveils mechanism behind deadly neuroendocrine prostate cancer

New research unveils mechanism behind deadly neuroendocrine prostate cancer

Discovery of stem-like CD4 T cells offers new hope for cancer immunotherapy

Discovery of stem-like CD4 T cells offers new hope for cancer immunotherapy

UTEP researchers develop low-cost biochip for cancer diagnosis

UTEP researchers develop low-cost biochip for cancer diagnosis

New pro-oxidant supplement shows promise in slowing prostate cancer progression

New pro-oxidant supplement shows promise in slowing prostate cancer progression

Semaglutide may lower Alzheimer's risk in type 2 diabetes patients

Semaglutide may lower Alzheimer's risk in type 2 diabetes patients

New CAR T cells offer controlled treatment for solid tumors

New CAR T cells offer controlled treatment for solid tumors

Higher diet quality associated with reduced risk of prostate cancer grade reclassification

Higher diet quality associated with reduced risk of prostate cancer grade reclassification

Study links healthy diet to reduced progression of low-risk prostate cancer

Study links healthy diet to reduced progression of low-risk prostate cancer

Innovative sensor material offers non-invasive cancer diagnosis

Innovative sensor material offers non-invasive cancer diagnosis

Black prostate cancer patients respond better to immunotherapy

Black prostate cancer patients respond better to immunotherapy

Innovative nanoparticle therapy offers hope in fighting prostate cancer

Innovative nanoparticle therapy offers hope in fighting prostate cancer

Early prostate cancer surgery linked to improved survival rates

Early prostate cancer surgery linked to improved survival rates

Research shows link between multiple sclerosis to increased risk of certain cancers

Research shows link between multiple sclerosis to increased risk of certain cancers

NCCN and LACOG collaborate to enhance cancer care in South America

NCCN and LACOG collaborate to enhance cancer care in South America

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.